HLA-B* 1502 FOR CARBAMAZEPINE TOXICITY GENE PANEL BY NGS, EDTA BLOOD

image not found

NABL Cap Accredited     
This test detects the presence of the HLA-B*1502 allele using Next-Generation Sequencing (NGS). The presence of this gene variant is strongly associated with an increased risk of severe adverse skin reactions such as Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in individuals treated with carbamazepine. Identifying carriers helps clinicians determine the safest medication choice and prevent life-threatening drug reactions. It is especially relevant before initiating carbamazepine therapy in susceptible populations

  • 17 Crores+ Samples Processed
  • World Class Technology Labs
  • 25+ Years of Trust & Experience
  • Free Home Collection

Price: Rs. 9,010.00

Sample Type: EDTA BLOOD

Fasting Not Required


Notes: H0861

Frequently Asked Questions (FAQ's):

What is the purpose of this test?
This test determines whether a person carries the HLA-B*1502 gene variant associated with severe skin reactions to carbamazepine.

Who should undergo this test?
Patients who are prescribed carbamazepine for epilepsy, neuropathic pain, or psychiatric conditions, especially those of Asian ancestry where the gene frequency is higher.

How is the test performed?
A blood sample collected in an EDTA tube is analyzed using Next-Generation Sequencing technology to detect the HLA-B*1502 allele.

What does a positive result indicate?
A positive result indicates increased risk of developing SJS/TEN if treated with carbamazepine, and alternative medications are recommended.

Is fasting required for this test?
No, fasting is not required

OUR corporates PARTNER

Feedback

Patient's Testimonials

Trusted by Thousands

OUR Accreditations

OUR Lab